Is Sarepta Therapeutics Worth the Risk?
Can Sarepta's highflying ways continue, or is it time to take profits?
Why Shares of Sarepta Therapeutics Inc Are Falling Today
A capital raise disappoints investors, sending shares lower.
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Which of these two companies will win the race to successfully develop the first Duchenne muscular dystrophy treatment? Our team of contributors weigh in.